Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716443 | 0.92 | PDE4D (0.52) | PDE4DPDE4BMAPK1CA12CA1 | |
| SCHEMBL3226491 | 0.87 | PDE4D (0.42) | PDE4DPDE4BMAPK1CA12CA1 | |
| SCHEMBL38663185 | 0.85 | PDE4D (0.53) | PDE4DPDE4BMAPK1CA12CA1 | |
| SCHEMBL3217956 | 0.84 | KDM4E (0.41) | PDE4DCA12CA1CA2CA7 | |
| SCHEMBL29241266 | 0.83 | POLB (0.45) | PDE4DLMNAHPGDGAANPC1 | |
| SCHEMBL24338701 | 0.83 | PDE4D (0.39) | PDE4DCA12CA1CA2CA7 | |
| SCHEMBL14684369 | 0.77 | PDE4D (0.43) | PDE4DMAPK1SMN1; SMN2LMNAHPGD | |
| SCHEMBL1290595 | 0.76 | DRD2 (0.60) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL21818303 | 0.75 | PDE4D (0.48) | PDE4DPDE4BMAPK1CA12CA1 | |
| SCHEMBL956204 | 0.75 | EGFR (0.55) | PDE4DPDE4BMAPK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | PDE4D 3757/4885PDE4B 3804/4885MAPK1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.